Moderna, a biotech company working on a coronavirus vaccine has reported positive results from phase 1 of the vaccine trial.
According to The Hill:
The biotech company Moderna on Monday reported “positive” data on its potential coronavirus vaccine from an early clinical trial, raising hopes about the effort.
The company said early data from a phase one clinical trial showed that people given the potential vaccine generated an immune response similar to that in people who had recovered from the disease.
The levels of neutralizing antibodies were “at or above” the levels seen in blood samples from people who have recovered from the coronavirus, Moderna said in a statement.
“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 [micrograms],” Tal Zaks, chief medical officer at Moderna, said in a statement.
The results were from the first 8 participants in the trial.
Image Credit: Featous / CC BY-SA (https://creativecommons.org/licenses/by-sa/4.0)